Aarti PharmaLabs Limited has published newspaper advertisements regarding its Second 100-Day Campaign 'Saksham Niveshak' in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed BSE and NSE on April 07, 2026, about the publication of advertisements in Financial Express (English) and Loksatta-Jansatta (Gujarati) on the same date.

Campaign Overview and Regulatory Compliance

The aarti pharma labs campaign, running from April 01 to July 09, 2026, follows a directive from the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs, dated March 27, 2026. The initiative focuses on proactive shareholder engagement by updating essential records, expediting dividend processing, preventing unwarranted share transfers to the IEPFA, and facilitating direct settlement of claims by the company.

Required Documentation and KYC Updates

Shareholders must update several key details to claim their unpaid dividends and prevent transfer to IEPF:

Since dividends are payable only through electronic mode, amounts will be credited to shareholders' bank accounts only after the required information and documents are updated. Shareholders can download necessary documents from the designated portal provided by MUFG Intime India Private Limited.

Contact Information and Support

For shareholders requiring assistance during the campaign, multiple contact channels are available:

Important Deadlines and Consequences

Shareholders must submit their documents by July 09, 2026, to support the campaign's success. The company has emphasized that dividend amounts remaining unclaimed for seven consecutive years will result in the corresponding equity shares being transferred to the IEPF Authority in accordance with Ministry of Corporate Affairs notifications. Shareholders whose unclaimed dividends or shares have already been transferred to IEPF can submit the prescribed Form IEPF-5 online and send physical documents to the company or registrar as per the process outlined on the IEPF website.

Aarti pharma labs promoter Mr. Mirik Rajendra Gogri has disclosed the creation of a pledge on company shares under SEBI regulations. The disclosure, submitted on March 31, 2026, pertains to the pledging of shares for personal borrowing purposes under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Details and Structure

The pledge involves 27,84,094 shares of Aarti Pharmalabs Limited, representing 3.08% of the company's total share capital. The encumbrance was created on March 25, 2026, in favor of two financial entities for third party pledge purposes.

Beneficiary Entities and Distribution

The pledged shares have been distributed between two financial institutions. Bajaj Financial Securities Limited received the larger portion with 26,16,700 shares, while 360 One Distribution Services Limited received 1,67,394 shares.

Financial Terms and Security Cover

The borrowing arrangement involves ₹75,00,00,000 against the pledged shares valued at ₹177,90,36,066 on the agreement date. This provides substantial security coverage for the lenders with a security cover ratio of 2.37.

Promoter Shareholding Context

As of December 31, 2025, Mr. Mirik Rajendra Gogri held 3,90,66,368 shares representing 43.10% of Aarti Pharmalabs Limited's total share capital. The current pledge represents 7% of his total promoter shareholding, which falls below the significant threshold levels requiring additional regulatory scrutiny.

The disclosure confirms that both beneficiary entities are recognized financial institutions, and the encumbrance is not related to any debt instruments such as debentures or commercial papers. The pledge arrangement follows standard regulatory compliance requirements under SEBI regulations for substantial acquisition of shares and takeovers.